The Soluble PlasminogenActivator Receptoras a Biomarker on Monitoring the Therapy Progress of Pulmonary TB-AFB(+) Patients

Abstract

The role of soluble soluble urokinase-type plasminogen activator receptor (suPAR) as a biological marker for TB treatment efficacy on active pulmonary TB-AFB(+) patients was investigated. Twenty pulmonary TB-AFB(+) patients participated in a cohort study for six months. The plasma suPAR level was measured using ELISA method before treatment, two months, four months and six months after treatment. At the same time clinical parameters were also measured. Results indicated that all patients (n = 20) showed highest plasma suPAR levels before treatment (median 12.775 ng/mL) and significantly decreased ( P = .0001<.05, R 2 = .890) after 2 months (median 8.019 ng/mL) and 4 months (median 5.771 ng/mL) of treatment, respectively. However, only slightly declined after 6 months therapy (median 5.009 ng/mL), near control group level (median 4.772 ng/mL). Interestingly, the significant reduced of suPAR level was parallel to treatment efficacy and correlated with other clinical and laboratory parameters, that is, decreasing of patients' complaints, increasing of BMI (r = −0.281), thoracic imaging improvement, sputum conversion, decreasing of ESR (r = 0.577) and monocytes count (r = 0.536) with exception the width of lesion in thoracic imaging. In conclusion, the suPAR level in could reflect the progress of TB therapy.

The Role of Serum Soluble Urokinase-Type Plasminogen Activator Receptor in Stable Chronic Obstructive Pulmonary Disease

“…Our findings were in agreement with the study by Mardining Raras and Noor, 32 which showed that mobilization of macrophages into the bronchi increased suPAR levels. Adherence and migration of monocytes were associated with a functional interaction between uPAR and integrins.…”

“…In summary, we found that serum suPAR levels were elevated in stable COPD, and no significant difference in theses levels was found between patients in GOLD stages II, III, and IV. Our findings were in agreement with the study by Mardining Raras and Noor, 32 which showed that mobilization of macrophages into the bronchi increased suPAR levels. Adherence and migration of monocytes were associated with a functional interaction between uPAR and integrins.…”

Soluble Urokinase Plasminogen Activator Receptor Levels in Tuberculosis Patients at High Risk for Multidrug Resistance

“…The therapy failure group showed the lowest suPAR levels, but these levels were still comparable with those of the cured TB patients from the previous study (5.32 ng/mL versus 5.09 ng/mL) [7]. Despite 40% of lesion widths being in the far-advanced category, only 10% of patients had MDR-positive cultures, with 40% culture positive although monoresistant or sensitive to an anti-TB drug.…”

“…Our previous study showed that suPAR could be used as a biomarker to monitor the progress of therapy in TB-AFB(+) patients [7]. The purpose of the present study was to observe the profile of suPAR levels in pulmonary TB patients at high risk for multidrug resistance including those with negative AFB conversion at two months, therapy failure and relapse, and compare it with the incidence of multidrug resistance.…”